The long-awaited results of the Trial Assigning Individualized Options for Treatment (TAILORx) definitively identified a vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.
> LEARN MORE
After a patient is diagnosed with breast cancer, doctors and patients work together to plan the best course of treatment. Along with other pieces of information, the OncotypeDX® Breast Recurrence Score Test can assist in deciding whether or not to make chemotherapy part of their treatment plan. The test can also help doctors determine the likelihood of the cancer returning in the future, also known as recurrence.
The OncotypeDX® Breast Recurrence Score Test works by examining a sample of breast cancer tissue. The test measures a group of breast cancer genes in this sample to see how active they are (also known as how they are expressed). The result of the test is reported as a number between 0 and 100, known as the Recurrence Score result. A lower score means the cancer has a lower chance of returning, and a higher score means that there is a higher chance of the cancer returning. The score also provides patients and doctors with important information regarding the potential benefit of adding chemotherapy to hormonal therapy. A low score indicates that the patient will receive minimal benefit from chemotherapy, whereas a patient with a high score can have significant benefit from chemotherapy. Because everyone's body and tumor are unique, obtaining a Recurrence Score result helps make treatment decisions tailored to the patient.
The OncotypeDX® Breast Recurrence Score Test provides information in addition to standard measurements (such as tumor size, tumor grade and lymph node status) that doctors have traditionally used to estimate how likely a patient's cancer is to return, and to help make treatment decisions.
The Oncotype DX® Breast Recurrence Score Test has been validated and provides level 1, category B evidence as defined by Simon et al. Consistent results across multiple well-designed studies demonstrate the assay’s robust analytic performance, clinical validity and clinical utility. As a result the assay has been incorporated into multiple guidelines including National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), National Institute for Health and Care Excellence (NICE), St. Gallen, and European Society for Medical Oncology (ESMO).
For more information please visit Oncotype DX®.
Genomic Health, Inc. (now trading as "Exact Sciences")
Oncotype DX Breast Recurrence Score, Oncotype DX and Recurrence Score are registered trademarks of Genomic Health, Inc.
Exact Sciences is a trademark or registered trademark of Exact Sciences Corporation. ©2020 Genomic Health, Inc. All rights reserved.
The expected TAT of the OncotypeDX® Breast Recurrence Score test results is up to 10 working days. (Greece, Cyprus, Romania & Turkey)
The Recurrence Score allows patients and physicians to determine the risk of developing a distant metastasis in 10 years for patients with ER+, lymph node 0-3, and HER2 negative, early stage breast cancer patients.
The Recurrence Score provides information on which patient benefits and which does not benefit from the addition of adjuvant chemotherapy to the treatment plan. This way, the treatment of the patient is individualized based on the biology of the tumor.
By testing every eligible patient after surgery, but before you discuss her treatment plan, you can make recommendations with increased insight and confidence.
Genomic Health, Inc. (now trading as "Exact Sciences")
Oncotype DX Breast Recurrence Score, Oncotype DX and Recurrence Score are registered trademarks of Genomic Health, Inc.
Exact Sciences is a trademark or registered trademark of Exact Sciences Corporation. ©2020 Genomic Health, Inc. All rights reserved.
NCCN
The only assay recognized to predict the benefit of adjuvant chemotherapy and the only assay classified as “recommended” in postmenopausal patients with N0/N1, HR+, HER2- breast cancer.
ASCO
The only test strongly recommended for all N0 and postmenopausal N1 patients with ER+, HER2- early breast cancer.
The recommendation is independent of clinical risk, with high quality evidence.
The ODX test is performed in the central laboratories of Genomic Health Inc. in California, USA.
The results are going to be available in 10 working days.
1 Paraffin block that contains the tumor tissue.
For information about the cost coverage of the test you should contact your personal insurance.
The payment can be made with a bank transfer or credit/debit card.
Genekor is responsible for all the necessary procedures of the collection and return of the patient’s specimen. Please contact us at : (Local phone/e-mail).
The results are being shared to the ordering physician via e-mail. If you need any support for your sample collection please contact us at : (local telephone/e-mail).
